“This collaboration underscores the unique potential of both native and engineered iNKT cells, allowing us to explore cutting-edge approaches that could significantly enhance clinical responses and deliver better outcomes for patients,” said Dr. Jennifer Buell, President and Chief Executive Officer at MiNK. “MiNK-215 and agenT-797 are novel cell therapies designed to overcome the limitations of traditional immune checkpoint inhibitors. Recent preclinical models of MSS colorectal cancer with metastatic liver disease demonstrated that these iNKT cells have the potential to eliminate tumor cells effectively. By combining them with Autonomous Therapeutics’ engineered RNA technology, we are confident that we can unlock even greater therapeutic possibilities and continue advancing our mission to transform the landscape of cell therapy.”
